Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer

International Journal of Cancer

Volumn 131, Issue 4, 2012, Pages

  Marmé, Frederik ^a   Hielscher, Thomas ^b   Hug, Sarah ^a   Bondong, Sandra ^b   Zeillinger, Robert ^c,d   Castillo Tong, Dan Cacsire ^c,d   Sehouli, Jalid ^e   Braicu, Ioana ^e   Vergote, Ignace ^f   Isabella, Cadron ^f   Mahner, Sven ^g   Ferschke, Irmgard ^a   Rom, Joachim ^a   Sohn, Christof ^a   Schneeweiss, Andreas ^a   Altevogt, Peter ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^d UNIVERSITY OF VIENNA   (Austria)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

FGFR4; ovarian cancer; OVCAD; polymorphism; prediction; prognosis; SNP

Indexed keywords

FIBROBLAST GROWTH FACTOR 4; PLATINUM;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; FGFR4 GENE; GENE FREQUENCY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; ONCOGENE; OVARY CANCER; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE;

ALLELES; ANTINEOPLASTIC AGENTS; ARGININE; DISEASE PROGRESSION; FEMALE; HUMANS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; SURVIVAL RATE;

EID: 84862536269     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27329     Document Type: Article

References (25)

1. Powers CJ, McLeskey SW, Wellstein A,. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000; 7: 165-97.
2. Burke D, Wilkes D, Blundell TL, Malcolm S,. Fibroblast growth factor receptors: lessons from the genes. Trends Biochem Sci 1998; 23: 59-62. (Pubitemid 28085228)
3. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, Muller S, Gartner S, Sures I, Wang H, Imyanitov E, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 2002; 62: 840-7. (Pubitemid 34126962)
4. Stadler CR, Knyazev P, Bange J, Ullrich A,. FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression. Cell Signal 2006; 18: 783-94. (Pubitemid 43208932)
5. Thussbas C, Nahrig J, Streit S, Bange J, Kriner M, Kates R, Ulm K, Kiechle M, Hoefler H, Ullrich A, Harbeck N,. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 2006; 24: 3747-55. (Pubitemid 46622313)
6. Ansell A, Farnebo L, Grenman R, Roberg K, Thunell LK,. Polymorphism of FGFR4 in cancer development and sensitivity to cisplatin and radiation in head and neck cancer. Oral Oncol 2009; 45: 23-9.
7. da Costa Andrade VC, Parise O, Jr., Hors CP, De Melo Martins PC, Silva AP, Garicochea B,. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol 2007; 82: 53-7. (Pubitemid 46038266)
8. Morimoto Y, Ozaki T, Ouchida M, Umehara N, Ohata N, Yoshida A, Shimizu K, Inoue H,. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 2003; 98: 2245-50. (Pubitemid 37392429)
9. Spinola M, Leoni V, Pignatiello C, Conti B, Ravagnani F, Pastorino U, Dragani TA,. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 2005; 23: 7307-11. (Pubitemid 46202344)
10. Streit S, Mestel DS, Schmidt M, Ullrich A, Berking C,. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer 2006; 94: 1879-86. (Pubitemid 43882579)
11. Wang J, Stockton DW, Ittmann M,. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 2004; 10: 6169-78. (Pubitemid 39287523)
12. Yang YC, Lu ML, Rao JY, Wallerand H, Cai L, Cao W, Pantuck A, Dalbagni G, Reuter V, Figlin RA, Belldegrun A, Cordon-Cardo C, et al. Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis. Br J Cancer 2006; 95: 1455-8. (Pubitemid 44863347)
13. Becker N, Nieters A, Chang-Claude J,. The fibroblast growth factor receptor gene Arg388 allele is not associated with early lymph node metastasis of breast cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 582-3. (Pubitemid 36713656)
14. Jezequel P, Campion L, Joalland MP, Millour M, Dravet F, Classe JM, Delecroix V, Deporte R, Fumoleau P, Ricolleau G,. G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. Br J Cancer 2004; 90: 189-93. (Pubitemid 38174960)
15. Matakidou A, El Galta R, Rudd MF, Webb EL, Bridle H, Eisen T, Houlston RS,. Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis. Br J Cancer 2007; 96: 1904-7. (Pubitemid 46912027)
16. Mawrin C, Kirches E, Diete S, Wiedemann FR, Schneider T, Firsching R, Kropf S, Bogerts B, Vorwerk CK, Kruger S, Dietzmann K,. Analysis of a single nucleotide polymorphism in codon 388 of the FGFR4 gene in malignant gliomas. Cancer Lett 2006; 239: 239-45. (Pubitemid 43974867)
17. Spinola M, Leoni VP, Tanuma J, Pettinicchio A, Frattini M, Signoroni S, Agresti R, Giovanazzi R, Pilotti S, Bertario L, Ravagnani F, Dragani TA,. FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncol Rep 2005; 14: 415-9.
18. Frullanti E, Berking C, Harbeck N, Jezequel P, Haugen A, Mawrin C, Parise O, Sasaki H, Tsuchiya N, Dragani TA,. Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor. Eur J Cancer Prev 2011; 20: 340-7.
19. Roidl A, Berger HJ, Kumar S, Bange J, Knyazev P, Ullrich A,. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res (An Official Journal of the American Association for Cancer Research) 2009; 15: 2058-66.
20. Seitzer N, Mayr T, Streit S, Ullrich A,. A single nucleotide change in the mouse genome accelerates breast cancer progression. Cancer Res 2010; 70: 802-12.
21. Marme F, Werft W, Benner A, Burwinkel B, Sinn P, Sohn C, Lichter P, Hahn M, Schneeweiss A,. FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Res Treat 2011. [Epub ahead of print].
22. Jaakkola S, Salmikangas P, Nylund S, Partanen J, Armstrong E, Pyrhonen S, Lehtovirta P, Nevanlinna H,. Amplification of fgfr4 gene in human breast and gynecological cancers. Int J Cancer 1993; 54: 378-82. (Pubitemid 23169673)
23. Streit S, Bange J, Fichtner A, Ihrler S, Issing W, Ullrich A,. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 2004; 111: 213-7. (Pubitemid 38924697)
24. Roidl A, Berger HJ, Kumar S, Bange J, Knyazev P, Ullrich A,. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res 2009; 15: 2058-66.
25. Seitzer N, Mayr T, Streit S, Ullrich A,. A single nucleotide change in the mouse genome accelerates breast cancer progression. Cancer Res 2010; 70: 802-12.